

2nd Alpine Winter Conference on Medicinal and Synthetic Chemistry

Confirmed Speakers

Keynote Speakers

Expanding the Druggable Genome through Cereblon-Mediated Protein Degradation (KL02)



Dr Lawrence G. HAMANN
(BRISTOL-MYERS SQUIBB, San Francisco, United States)

Necessity is the Mother of Invention: Natural Products and the Chemistry They Inspire (KL01)



Prof. Sarah E. REISMAN
(CALIFORNIA INSTITUTE OF TECHNOLOGY, Pasadena, United States)

Controlling the Fate and Function of Proteins with Photopharmacology (KL03)



Prof. Dirk TRAUNER
(NEW YORK UNIVERSITY, New York, United States)

Accelerating Drug Discovery by Intelligence Augmentation

Exploring an Interface of Synthesis and Data Science (PL18)



Prof. Timothy CERNAK
(UNIVERSITY OF MICHIGAN, Ann Arbor, United States)

Organic Synthesis on a Computer: Should Medicinal Chemists Care? (PL17)



Prof. Bartosz A. GRZYBOWSKI
(ULSAN NATIONAL INSTITUTE OF SCIENCE & TECHNOLOGY, Ulsan, Korea, South)

Accelerating R&D with Augmented Intelligence (PL19)



Dr Matthias ZENTGRAF
(BOEHRINGER INGELHEIM, Biberach an der Riss, Germany)

Drug Discovery Tales

The Big Impact of Small Changes : Towards Best-in-Class EZH2 and LSD1 Inhibitors (OC08)



Dr Julian LEVELL
(CONSTELLATION PHARMACEUTICALS, Cambridge, United States)

Discovery of AZD3458 a Highly Selective PI3Ky Inhibitor: Combining Structure, HDX-MS and Binding Kinetics to Understand the Mode of Action (OC06)



Dr Nils PEMBERTON
(ASTRAZENECA, Mölndal, Sweden)

2nd Alpine Winter Conference on Medicinal and Synthetic Chemistry

Confirmed Speakers

The Discovery of a Potent and Orally Bioavailable Macrocyclic Cyclophilin Inhibitor Based on The Structural Simplification of Sanglifehrin A (OC07)



Dr Vicky STEADMAN
(EUROFINS DISCOVERY, Macclesfield, United Kingdom)

Investigating the Chameleonic Properties of RGD Integrin Antagonists for the Treatment of IPF (OC05)



Dr James THOMPSON
(GLAXOSMITHKLINE/UNIVERSITY OF STRATHCLYDE, Stevenage, United Kingdom)

Discovery of GDC-0334: a potent and orally bioavailable clinical candidate for the inhibition of TRPA1 (OC04)



Dr Vishal VERMA
(GENENTECH, South San Francisco, United States)

Frontiers of Synthetic Chemistry

A Radical Way to Abeo-Steroids (PL08)



Prof. Philipp HERETSCH
(FREE UNIVERSITY OF BERLIN, Berlin, Germany)

New Avenues in Synthesis Enabled by Organic Photoredox Catalysis (PL06)



Prof. David NICEWICZ
(UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, Chapel Hill, United States)

Late-Stage Functionalizations (PL07)



Prof. Tobias RITTER
(MAX-PLANCK-INSTITUT FÜR KOHLENFORSCHUNG, Mulheim, Germany)

Break-it-to-Make-it Strategies for Complex Molecule Synthesis (PL05)



Prof. Richmond SARPONG
(UNIVERSITY OF CALIFORNIA, BERKELEY, Berkeley, United States)

Innovation and Inspiration from Natural Products

Capturing Biological Activity in Natural Product Fragments: Success and Limitations (PL14)



Prof. Karl GADEMANN
(UNIVERSITY OF ZÜRICH, Zürich, Switzerland)

(De)Construction of Three-Dimensional Molecular Architectures (PL15)

2nd Alpine Winter Conference on Medicinal and Synthetic Chemistry

Confirmed Speakers



Prof. Thomas MAGAUER
(UNIVERSITY OF INNSBRUCK, Innsbruck, Austria)

Synthesis of Complex Antiplasmodial Isocyanoterpenes (PL16)



Prof. Christopher VANDERWAL
(UNIVERSITY OF CALIFORNIA, Irvine, United States)

Total Synthesis of Chivosazole F (OC03)



Dr Simon WILLIAMS
(SYNGENTA, Stein AG, Switzerland)

Predictive ADME Sciences: Striking a Balance Between In Silico and Experimental Work?

Structural Attributes Influencing Unbound Tissue Distribution (PL01)



Dr Li DI
(PFIZER, Groton, United States)

Metabolism of Strained Rings: Tales of the Unexpected (PL02)



Dr Martin HAYES
(ASTRAZENECA, Gothenburg, Sweden)

Predicting ADME - Reality, Vision or Fantasy? (PL04)



Dr Simone SCHADT
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

Leveraging In Silico ADMET Profiles and Ancillary Pharmacology to Influence Prioritization of Hit Series with Higher Probability of Success (PL03)



Dr Falgun SHAH
(MERCK & CO., West Point, United States)



Dr Kenichi UMEHARA
(ROCHE PHARMACEUTICAL RESEARCH AND EARLY DEVELOPMENT, Basel, Switzerland)

Protein Degradation: New Rules for Drug Discovery

Expanding the Druggable Genome through Cereblon-Mediated Protein Degradation (KL02)

2nd Alpine Winter Conference on Medicinal and Synthetic Chemistry

Confirmed Speakers



Dr Lawrence G. HAMANN
(BRISTOL-MYERS SQUIBB, San Francisco, United States)

Targeted Protein Degradation (PL12)



Prof. Andy PHILLIPS
(C4 THERAPEUTICS, Watertown, United States)

Four E3 Ligases, One Target: Towards Novel CDK6 Protacs (OC02)



Dr Christian STEINEBACH
(UNIVERSITY OF BONN, Bonn, Germany)

Chemical Genomics Approaches to Targeted Protein Degradation (PL13)



Dr Georg WINTER
(RESEARCH CENTER FOR MOLECULAR MEDICINE OF THE AUSTRIAN ACADEMY OF SCIENCES, Vienna, Austria)

Structure and Biophysics - Companions for Medicinal Chemistry

Membrane Proteins at the SGC – Challenges and Success Stories (PL09)



Dr Katharina DÜRR
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

Discovery of Small Molecule Fascin 1 Inhibitors Using Fragment-Based Drug Discovery (OC01)



Dr Stuart FRANCIS
(THE BEATSON INSTITUTE FOR CANCER RESEARCH, Glasgow, United Kingdom)

The Mechanism of Outer Membrane Protein Insertion by BamA and its Role as a Target for Novel Antibiotic (PL10)



Prof. Sebastian HILLER
(UNIVERSITY OF BASEL, Basel, Switzerland)

Discovery of ABL001, an Allosteric Inhibitor of BCR-ABL: Fragments, Biophysics, Structure and Chemistry (PL11)



Dr Wolfgang JAHNKE
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)

Targeted Delivery - Strategies to Help your Drug Substances get to the Right Place

Using Small Molecules to Engineer and Explore Human Immunity (PL20)

2nd Alpine Winter Conference on Medicinal and Synthetic Chemistry

Confirmed Speakers



(BIOIBÉRICA)

Prof. David SPIEGEL
(YALE UNIVERSITY, New Haven, United States)

Intracellular and Tissue Specific Targeting of Therapeutic Modalities (PL22)



Dr Vadim DUDKIN
(JANSSEN DISCOVERY SCIENCES, Lansdale, United States)

SBT6050, a HER2-Directed TLR8 Immunotac™ Therapeutic, is a Potent Human Myeloid Cell Agonist with Tumor-Localized Activity (PL23)



Dr Valerie ODEGARD
(SILVERBACK THERAPEUTICS, Seattle, United States)

Discovery of Tumor-Targeted TLR7/8 Immune-Stimulating Antibody Conjugates (ISAC): A New Class of Immuno-Oncology Therapeutics (PL21)



Dr Brian SAFINA
(BOLT BIOTHERAPEUTICS, Redwood City, United States)